{
    "nct_id": "NCT05169684",
    "official_title": "A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer",
    "inclusion_criteria": "* Histologic confirmation of carcinoma of the prostate without small cell features\n* Documented prostate cancer progression by Prostate Cancer Working Group 3 (PCWG3) criteria while castrate\n* Evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography (CT)/magnetic resonance imaging (MRI)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or bilateral orchiectomy (i.e., surgical or medical castration) confirmed by testosterone level â‰¤ 1.73 nmol/L (50 ng/dL) at the screening visit\n* Chemotherapy-naive for metastatic castration-resistant prostate cancer (mCRPC) and have received at least one novel antiandrogen therapy (NAT)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment in Part 1 or randomization in Part 2\n* Untreated central nervous system (CNS) metastases\n* Leptomeningeal metastases\n* Active, known or suspected autoimmune disease\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}